Riverwater Partners LLC Has $390,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Riverwater Partners LLC lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 5,410 shares of the medical equipment provider’s stock after selling 172 shares during the period. Riverwater Partners LLC’s holdings in Hologic were worth $390,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of HOLX. General Partner Inc. bought a new position in Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment grew its stake in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC increased its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 1.3 %

Shares of HOLX stock opened at $60.86 on Friday. The stock has a market cap of $13.66 billion, a P/E ratio of 19.20, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 1 year low of $59.06 and a 1 year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a 50 day simple moving average of $64.30 and a 200 day simple moving average of $72.65.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HOLX. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Evercore ISI dropped their price objective on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. Citigroup reduced their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Royal Bank of Canada dropped their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Finally, Stephens reaffirmed an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.